The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11033 malaria professionals are enjoying the free benefits of MalariaWorld today

Covid-19

The potential public health consequences of COVID-19 on malaria in Africa

August 10, 2020 - 16:04 -- Open Access
Author(s): 
Sherrard-Smith E, Hogan AB, Churcher TS, et al.
Reference: 
Nat Med. 2020 Aug 7

The burden of malaria is heavily concentrated in sub-Saharan Africa (SSA) where cases and deaths associated with COVID-19 are rising1. In response, countries are implementing societal measures aimed at curtailing transmission of SARS-CoV-22,3. Despite these measures, the COVID-19 epidemic could still result in millions of deaths as local health facilities become overwhelmed4.

Bacillus Calmette-Guérin vaccine, antimalarial, age and gender relation to COVID-19 spread and mortality

August 4, 2020 - 15:06 -- Open Access
Author(s): 
Osama El-Gendy A, Saeed H, Ali AMA, Zawbaa HM, Gomaa D, Harb HS, Madney YM, Osama H, Abdelrahman MA, Abdelrahim MEA
Reference: 
Vaccine. 2020 Jul 31;38(35):5564-5568

COVID-19 is affecting different countries all over the world with great variation in infection rate and death ratio. Some reports suggested a relation between the Bacillus Calmette-Guérin (BCG) vaccine and the malaria treatment to the prevention of SARS-CoV-2 infection. Some reports related infant's lower susceptibility to the COVID-19.

Identifying and combating the impacts of COVID-19 on malaria

July 30, 2020 - 14:03 -- Open Access
Author(s): 
Rogerson SJ, Beeson JG, Laman M, Poespoprodjo JR, William T, Simpson JA, Price RN; ACREME Investigators
Reference: 
BMC Med. 2020 Jul 30; 18(1):239

The COVID-19 pandemic has resulted in millions of infections, hundreds of thousands of deaths and major societal disruption due to lockdowns and other restrictions introduced to limit disease spread. Relatively little attention has been paid to understanding how the pandemic has affected treatment, prevention and control of malaria, which is a major cause of death and disease and predominantly affects people in less well-resourced settings.

Artemisia Spp. Derivatives for COVID-19 Treatment: Anecdotal Use, Political Hype, Treatment Potential, Challenges, and Road Map to Randomized Clinical Trials

July 29, 2020 - 10:14 -- Open Access
Author(s): 
Kapepula PM, Kabengele JK, Nachega JB, et al.
Reference: 
Am J Trop Med Hyg. 2020 Jul 23

The world is currently facing a novel COVID-19 pandemic caused by SARS-CoV-2 that, as of July 12, 2020, has caused a reported 12,322,395 cases and 556,335 deaths. To date, only two treatments, remdesivir and dexamethasone, have demonstrated clinical efficacy through randomized controlled trials (RCTs) in seriously ill patients. The search for new or repurposed drugs for treatment of COVID-19 continues.

NOT Open Access | Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia

July 27, 2020 - 12:13 -- NOT Open Access
Author(s): 
Stremmel C, Kellnar A, Massberg S, Kääb S
Reference: 
J Cardiovasc Pharmacol Ther. 2020 Jul 23:1074248420935740

In recent months, the new coronavirus SARS-CoV-2 has emerged as a worldwide threat with about 4.2 million confirmed cases and almost 300 000 deaths. Its major clinical presentation is characterized by respiratory symptoms ranging from mild cough to serve pneumonia with fever and potentially even death. Until today, there is no known medication to improve clinical symptoms or even prevent or fight the infection.

Chloroquine and Hydroxychloroquine in Coronavirus Disease 2019 (COVID-19). Facts, Fiction & the Hype. A Critical Appraisal

July 21, 2020 - 15:23 -- Open Access
Author(s): 
Khuroo MS, Sofi AA, Khuroo M
Reference: 
Int J Antimicrob Agents. 2020 Jul 17:106101

The coronavirus infection (COVID-19) has turned in to a global catastrophe and there is an intense search for effective drug therapy. Of all the potential therapies, chloroquine and hydroxychloroquine have been the focus of tremendous public attention. Both drugs have been used in the treatment and prophylaxis of malaria and long-term use of hydroxychloroquine is the cornerstone in the treatment of several auto-immune disorders.

Insights in chloroquine action: perspectives and implications in Malaria and COVID-19

July 21, 2020 - 12:08 -- Open Access
Author(s): 
Pillat MM, Krüger A, Guimarães LMF, Lameu C, de Souza EE, Wrenger C, Ulrich H
Reference: 
Cytometry A. 2020 Jul 19

Malaria is a threat to human mankind and kills about half a million people every year. On the other hand, COVID‐19 resulted in several hundred thousand deaths since December 2019 and remains without an efficient and safe treatment. The antimalarials chloroquine (CQ) and its analogue, hydroxychloroquine (HCQ), have been tested for COVID‐19 treatment, and several conflicting evidence has been obtained.

HIV, tuberculosis, and malaria: how can the impact of COVID-19 be minimised

July 20, 2020 - 15:17 -- Open Access
Author(s): 
Sands P
Reference: 
Lancet Glob Health. 2020 Jul 13:S2214-109X (20)30317-X

In The   Lancet   Global   Health,   Alexandra   Hogan   and   colleagues1  report  the  findings  of  a  modelling  study  in  which  they  estimate  the  number  of  excess  deaths  from  HIV,  tuberculosis,  and  malaria  that  could  plausibly  occur   as   a   consequence   of   the   COVID-19   pandemic.  

NOT Open Access | Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine; from HIV-1 infection to COVID-19

July 7, 2020 - 14:01 -- NOT Open Access
Author(s): 
Naghipour S, Ghodousi M, Rahsepar S, Elyasi S
Reference: 
Expert Rev Anti Infect Ther. 2020 Jul 7

Chloroquine (CQ) and hydroxychloroquine (HCQ), originally were prescribed for prevention or treatment of malaria, but now successfully are used in several rheumatologic diseases. In addition, in recent decades considering their immunomodulatory effects, high tolerably and low cost, they are evaluated for various viral infections from HIV to COVID-19.

Pages

Subscribe to RSS - Covid-19